The high prevalence of comorbidities such as diabetes and chronic kidney disease (CKD) in AMI patients further exacerbates the risk of CIN, highlighting the need for effective preventive measures.[6] Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of glucose-lowering agents used to treat type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and diabetes mellitus.